{
  "symbol": "UNH",
  "year": 2025,
  "Period": "Q1",
  "report_type": "Q10",
  "metrics": {
    "mdna_sentiment": 0.0,
    "outlook_sentiment": 0.2147,
    "forward_ratio": 1.0,
    "hedge_ratio": 0.196
  },
  "top_positive": [
    {
      "sent": "FINANCIAL STATEMENTS UnitedHealth Group Condensed Consolidated Balance Sheets (Unaudited) (in millions, except per share data) June 30, 2025 December 31, 2024 Assets Current assets: Cash and cash equivalents $ 28,596 $ 25,312 Short-term investments 3,424 3,801 Accounts receivable, net 24,142 22,365 Other current receivables, net 28,582 26,089 Prepaid expenses and other current assets 8,955 8,212 Total current assets 93,699 85,779 Long-term investments 52,466 52,354 Property, equipment and capitalized software, net 10,923 10,553 Goodwill 107,677 106,734 Other intangible assets, net 22,510 23,268 Other assets 21,298 19,590 Total assets $ 308,573 $ 298,278 Liabilities, redeemable noncontrolling interests and equity Current liabilities: Medical costs payable $ 38,427 $ 34,224 Accounts payable and accrued liabilities 34,330 34,337 Short-term borrowings and current maturities of long-term debt 5,698 4,545 Unearned revenues 3,032 3,317 Other current liabilities 29,294 27,346 Total current liabilities 110,781 103,769 Long-term debt, less current maturities 73,495 72,359 Deferred income taxes 3,804 3,620 Other liabilities 15,709 15,939 Total liabilities 203,789 195,687 Commitments and contingencies (Note 7) Redeemable noncontrolling interests 4,315 4,323 Equity: Preferred stock, $ 0.001 par value - 10 shares authorized; no shares issued or outstanding \u2014 \u2014 Common stock, $ 0.01 par value - 3,000 shares authorized; 905 and 915 issued and outstanding 9 9 Retained earnings 97,250 96,036 Accumulated other comprehensive loss ( 2,535 ) ( 3,387 ) Nonredeemable noncontrolling interests 5,745 5,610 Total equity 100,469 98,268 Total liabilities, redeemable noncontrolling interests and equity $ 308,573 $ 298,278 See Notes to the Condensed Consolidated Financial Statements 1 Table of Contents UnitedHealth Group Condensed Consolidated Statements of Operations (Unaudited) Three Months Ended June 30, Six Months Ended June 30, (in millions, except per share data) 2025 2024 2025 2024 Revenues: Premiums $ 87,905 $ 76,897 $ 174,439 $ 154,885 Products 13,564 12,211 26,600 24,120 Services 9,039 8,750 18,011 17,638 Investment and other income 1,108 997 2,141 2,008 Total revenues 111,616 98,855 221,191 198,651 Operating costs: Medical costs 78,585 65,458 151,996 131,193 Operating costs 13,778 13,162 27,372 27,239 Cost of products sold 13,019 11,340 25,409 22,396 Depreciation and amortization 1,084 1,020 2,145 2,017 Total operating costs 106,466 90,980 206,922 182,845 Earnings from operations 5,150 7,875 14,269 15,806 Interest expense ( 1,027 ) ( 985 ) ( 2,025 ) ( 1,829 ) Loss on sale of subsidiary and subsidiaries held for sale ( 41 ) ( 1,225 ) ( 56 ) ( 8,311 ) Earnings before income taxes 4,082 5,665 12,188 5,666 Provision for income taxes ( 510 ) ( 1,244 ) ( 2,142 ) ( 2,466 ) Net earnings 3,572 4,421 10,046 3,200 Earnings attributable to noncontrolling interests ( 166 ) ( 205 ) ( 348 ) ( 393 ) Net earnings attributable to UnitedHealth Group common shareholders $ 3,406 $ 4,216 $ 9,698 $ 2,807 Earnings per share attributable to UnitedHealth Group common shareholders: Basic $ 3.76 $ 4.58 $ 10.66 $ 3.05 Diluted $ 3.74 $ 4.54 $ 10.61 $ 3.02 Basic weighted-average number of common shares outstanding 907 921 910 921 Dilutive effect of common share equivalents 3 7 4 8 Diluted weighted-average number of common shares outstanding 910 928 914 929 Anti-dilutive shares excluded from the calculation of dilutive effect of common share equivalents 13 8 10 7 See Notes to the Condensed Consolidated Financial Statements 2 Table of Contents UnitedHealth Group Condensed Consolidated Statements of Comprehensive Income (Unaudited) Three Months Ended June 30, Six Months Ended June 30, (in millions) 2025 2024 2025 2024 Net earnings $ 3,572 $ 4,421 $ 10,046 $ 3,200 Other comprehensive income: Gross unrealized gains (losses) on investment securities during the period 327 ( 75 ) 848 ( 365 ) Income tax effect ( 75 ) 17 ( 194 ) 85 Total unrealized gains (losses), net of tax 252 ( 58 ) 654 ( 280 ) Gross reclassification adjustment for net realized gains included in net earnings ( 17 ) ( 26 ) ( 27 ) ( 58 ) Income tax effect 4 6 6 13 Total reclassification adjustment, net of tax ( 13 ) ( 20 ) ( 21 ) ( 45 ) Foreign currency translation gains (losses) 131 8 219 ( 285 ) Reclassification adjustment for translation losses included in net earnings \u2014 86 \u2014 4,214 Total foreign currency translation gains 131 94 219 3,929 Other comprehensive income 370 16 852 3,604 Comprehensive income 3,942 4,437 10,898 6,804 Comprehensive income attributable to noncontrolling interests ( 166 ) ( 205 ) ( 348 ) ( 393 ) Comprehensive income attributable to UnitedHealth Group common shareholders $ 3,776 $ 4,232 $ 10,550 $ 6,411 See Notes to the Condensed Consolidated Financial Statements 3 Table of Contents UnitedHealth Group Condensed Consolidated Statements of Changes in Equity (Unaudited) Common Stock Additional Paid-In Capital Retained Earnings Accumulated Other Comprehensive Loss Nonredeemable Noncontrolling Interests Total Equity Three months ended June 30, (in millions) Shares Amount Net Unrealized (Losses) Gains on Investments Foreign Currency Translation (Losses) Gains Balance at March 31, 2025 910 $ 9 $ \u2014 $ 97,934 $ ( 1,832 ) $ ( 1,073 ) $ 5,773 $ 100,811 Net earnings 3,406 149 3,555 Other comprehensive income 239 131 370 Issuances of common stock, and related tax effects 1 \u2014 196 196 Share-based compensation 229 229 Common share repurchases ( 6 ) \u2014 ( 415 ) ( 2,090 ) ( 2,505 ) Cash dividends paid on common shares ($ 2.21 per share) ( 2,000 ) ( 2,000 ) Redeemable noncontrolling interests fair value and other adjustments ( 10 ) ( 10 ) Acquisition and other adjustments of nonredeemable noncontrolling interests ( 19 ) ( 19 ) Distribution to nonredeemable noncontrolling interests ( 158 ) ( 158 ) Balance at June 30, 2025 905 $ 9 $ \u2014 $ 97,250 $ ( 1,593 ) $ ( 942 ) $ 5,745 $ 100,469 Balance at March 31, 2024 920 $ 9 $ \u2014 $ 90,118 $ ( 2,218 ) $ ( 1,221 ) $ 5,682 $ 92,370 Net earnings 4,216 158 4,374 Other comprehensive (loss) income ( 78 ) 94 16 Issuances of common stock, and related tax effects 1 \u2014 196 196 Share-based compensation 210 210 Common share repurchases \u2014 \u2014 3 1 4 Cash dividends paid on common shares ($ 2.10 per share) ( 1,935 ) ( 1,935 ) Redeemable noncontrolling interests fair value and other adjustments ( 36 ) ( 36 ) Acquisition and other adjustments of nonredeemable noncontrolling interests ( 338 ) ( 338 ) Distribution to nonredeemable noncontrolling interests ( 185 ) ( 185 ) Balance at June 30, 2024 921 $ 9 $ 373 $ 92,400 $ ( 2,296 ) $ ( 1,127 ) $ 5,317 $ 94,676 See Notes to the Condensed Consolidated Financial Statements 4 Table of Contents UnitedHealth Group Condensed Consolidated Statements of Changes in Equity (Unaudited) Common Stock Additional Paid-In Capital Retained Earnings Accumulated Other Comprehensive Loss Nonredeemable Noncontrolling Interests Total Equity Six months ended June 30, (in millions) Shares Amount Net Unrealized (Losses) Gains on Investments Foreign Currency Translation (Losses) Gains Balance at January 1, 2025 915 $ 9 $ \u2014 $ 96,036 $ ( 2,226 ) $ ( 1,161 ) $ 5,610 $ 98,268 Net earnings 9,698 297 9,995 Other comprehensive income 633 219 852 Issuances of common stock, and related tax effects 2 \u2014 379 379 Share-based compensation 591 591 Common share repurchases ( 12 ) \u2014 ( 955 ) ( 4,572 ) ( 5,527 ) Cash dividends paid on common shares ($ 4.31 per share) ( 3,912 ) ( 3,912 ) Redeemable noncontrolling interests fair value and other adjustments ( 15 ) ( 15 ) Acquisition and other adjustments of nonredeemable noncontrolling interests 175 175 Distribution to nonredeemable noncontrolling in\ne segment.",
      "score": 0.9985
    },
    {
      "sent": "The following table summarizes the impact of hypothetical changes in market interest rates across the entire yield curve by 1% point or 2% points as of June\u00a030, 2025 on our investment income and interest expense per annum, and the fair value of our investments and debt (in millions, except percentages): June 30, 2025 Increase (Decrease) in Market Interest Rate Investment Income\u00a0Per Annum Interest Expense\u00a0Per Annum Fair\u00a0Value\u00a0of Financial Assets Fair\u00a0Value\u00a0of Financial Liabilities 2 % $ 734 $ 542 $ (4,202) $ (9,288) 1 367 271 (2,150) (5,058) (1) (367) (256) 2,202 6,107 (2) (734) (510) 4,416 13,549 Note: The impact of hypothetical changes in interest rates may not reflect the full 100 or 200 basis point change on interest income and interest expense or on the fair value of financial assets and liabilities as the rates are assumed to not fall below zero.",
      "score": 0.9876
    },
    {
      "sent": "The following table summarizes the impact of hypothetical changes in market interest rates across the entire yield curve by 1% point or 2% points as of June\u00a030, 2025 on our investment income and interest expense per annum, and the fair value of our investments and debt (in millions, except percentages): June 30, 2025 Increase (Decrease) in Market Interest Rate Investment Income\u00a0Per Annum Interest Expense\u00a0Per Annum Fair\u00a0Value\u00a0of Financial Assets Fair\u00a0Value\u00a0of Financial Liabilities 2 % $ 734 $ 542 $ (4,202) $ (9,288) 1 367 271 (2,150) (5,058) (1) (367) (256) 2,202 6,107 (2) (734) (510) 4,416 13,549 Note: The impact of hypothetical changes in interest rates may not reflect the full 100 or 200 basis point change on interest income and interest expense or on the fair value of financial assets and liabilities as the rates are assumed to not fall below zero.",
      "score": 0.9876
    }
  ],
  "top_negative": [
    {
      "sent": "We discuss these matters, and certain risks that may affect our business operatio\nok Ratings Outlook Senior unsecured debt A2 Negative A+ Negative A Stable A Negative Commercial paper P-1 n/a A-1 n/a F1 n/a AMB-1+ n/a The availability of financing in the form of debt or equity is influenced by many factors, including our profitability, operating cash flows, debt levels, credit ratings, debt covenants and other contractual restrictions, regulatory requirements and economic and market conditions.",
      "score": -0.9382
    },
    {
      "sent": "Best Ratings Outlook Ratings Outlook Ratings Outlook Ratings Outlook Senior unsecured debt A2 Negative A+ Negative A Stable A Negative Commercial paper P-1 n/a A-1 n/a F1 n/a AMB-1+ n/a The availability of financing in the form of debt or equity is influenced by many factors, including our profitability, operating cash flows, debt levels, credit ratings, debt covenants and other contractual restrictions, regulatory requirements and economic and market conditions.",
      "score": -0.9118
    },
    {
      "sent": "Best Ratings Outlook Ratings Outlook Ratings Outlook Ratings Outlook Senior unsecured debt A2 Negative A+ Negative A Stable A Negative Commercial paper P-1 n/a A-1 n/a F1 n/a AMB-1+ n/a The availability of financing in the form of debt or equity is influenced by many factors, including our profitability, operating cash flows, debt levels, credit ratings, debt covenants and other contractual restrictions, regulatory requirements and economic and market conditions.",
      "score": -0.9118
    }
  ],
  "forward_snippets": [
    "Readers are cautioned that the statements, estimates, projections or outlook contained in this Management's Discussion and Analysis of Financial Condition and Results of Operations, including discussions regarding financial prospects, economic conditions, trends and uncertainties contained in this Item\u00a02, may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA).",
    "We expect overall spending on health care to continue to grow in the future, due to inflation, medical technology and pharmaceutical advancement, regulatory requirements, demographic trends in the population and national interest in health and well-being.",
    "We expect broad-based competition to continue as the industry adapts to individual and employer needs.",
    "16 Table of Contents Optum Health\u2019s fully accountable value-based care businesses have been impacted by Medicare funding reductions and have also seen continued medical cost trend pressures, which may impact future pricing in the markets we continue to participate.",
    "We continue to take a prudent, market-sustainable posture for both new business and maintenance of existing relationships."
  ],
  "curated_text": "Symbol: UNH. Year: 2025. Period: Q1. ReportType: Q10. Section: Management Discussion and Analysis (MD&A). Key metrics include sentiment, forward outlook, and risk hedging.  Top positive sentences: FINANCIAL STATEMENTS UnitedHealth Group Condensed Consolidated Balance Sheets (Unaudited) (in millions, except per share data) June 30, 2025 December 31, 2024 Assets Current assets: Cash and cash equivalents $ 28,596 $ 25,312 Short-term investments 3,424 3,801 Accounts receivable, net 24,142 22,365 Other current receivables, net 28,582 26,089 Prepaid expenses and other current assets 8,955 8,212 Total current assets 93,699 85,779 Long-term investments 52,466 52,354 Property, equipment and capitalized software, net 10,923 10,553 Goodwill 107,677 106,734 Other intangible assets, net 22,510 23,268 Other assets 21,298 19,590 Total assets $ 308,573 $ 298,278 Liabilities, redeemable noncontrolling interests and equity Current liabilities: Medical costs payable $ 38,427 $ 34,224 Accounts payable and accrued liabilities 34,330 34,337 Short-term borrowings and current maturities of long-term debt 5,698 4,545 Unearned revenues 3,032 3,317 Other current liabilities 29,294 27,346 Total current liabilities 110,781 103,769 Long-term debt, less current maturities 73,495 72,359 Deferred income taxes 3,804 3,620 Other liabilities 15,709 15,939 Total liabilities 203,789 195,687 Commitments and contingencies (Note 7) Redeemable noncontrolling interests 4,315 4,323 Equity: Preferred stock, $ 0.001 par value - 10 shares authorized; no shares issued or outstanding \u2014 \u2014 Common stock, $ 0.01 par value - 3,000 shares authorized; 905 and 915 issued and outstanding 9 9 Retained earnings 97,250 96,036 Accumulated other comprehensive loss ( 2,535 ) ( 3,387 ) Nonredeemable noncontrolling interests 5,745 5,610 Total equity 100,469 98,268 Total liabilities, redeemable noncontrolling interests and equity $ 308,573 $ 298,278 See Notes to the Condensed Consolidated Financial Statements 1 Table of Contents UnitedHealth Group Condensed Consolidated Statements of Operations (Unaudited) Three Months Ended June 30, Six Months Ended June 30, (in millions, except per share data) 2025 2024 2025 2024 Revenues: Premiums $ 87,905 $ 76,897 $ 174,439 $ 154,885 Products 13,564 12,211 26,600 24,120 Services 9,039 8,750 18,011 17,638 Investment and other income 1,108 997 2,141 2,008 Total revenues 111,616 98,855 221,191 198,651 Operating costs: Medical costs 78,585 65,458 151,996 131,193 Operating costs 13,778 13,162 27,372 27,239 Cost of products sold 13,019 11,340 25,409 22,396 Depreciation and amortization 1,084 1,020 2,145 2,017 Total operating costs 106,466 90,980 206,922 182,845 Earnings from operations 5,150 7,875 14,269 15,806 Interest expense ( 1,027 ) ( 985 ) ( 2,025 ) ( 1,829 ) Loss on sale of subsidiary and subsidiaries held for sale ( 41 ) ( 1,225 ) ( 56 ) ( 8,311 ) Earnings before income taxes 4,082 5,665 12,188 5,666 Provision for income taxes ( 510 ) ( 1,244 ) ( 2,142 ) ( 2,466 ) Net earnings 3,572 4,421 10,046 3,200 Earnings attributable to noncontrolling interests ( 166 ) ( 205 ) ( 348 ) ( 393 ) Net earnings attributable to UnitedHealth Group common shareholders $ 3,406 $ 4,216 $ 9,698 $ 2,807 Earnings per share attributable to UnitedHealth Group common shareholders: Basic $ 3.76 $ 4.58 $ 10.66 $ 3.05 Diluted $ 3.74 $ 4.54 $ 10.61 $ 3.02 Basic weighted-average number of common shares outstanding 907 921 910 921 Dilutive effect of common share equivalents 3 7 4 8 Diluted weighted-average number of common shares outstanding 910 928 914 929 Anti-dilutive shares excluded from the calculation of dilutive effect of common share equivalents 13 8 10 7 See Notes to the Condensed Consolidated Financial Statements 2 Table of Contents UnitedHealth Group Condensed Consolidated Statements of Comprehensive Income (Unaudited) Three Months Ended June 30, Six Months Ended June 30, (in millions) 2025 2024 2025 2024 Net earnings $ 3,572 $ 4,421 $ 10,046 $ 3,200 Other comprehensive income: Gross unrealized gains (losses) on investment securities during the period 327 ( 75 ) 848 ( 365 ) Income tax effect ( 75 ) 17 ( 194 ) 85 Total unrealized gains (losses), net of tax 252 ( 58 ) 654 ( 280 ) Gross reclassification adjustment for net realized gains included in net earnings ( 17 ) ( 26 ) ( 27 ) ( 58 ) Income tax effect 4 6 6 13 Total reclassification adjustment, net of tax ( 13 ) ( 20 ) ( 21 ) ( 45 ) Foreign currency translation gains (losses) 131 8 219 ( 285 ) Reclassification adjustment for translation losses included in net earnings \u2014 86 \u2014 4,214 Total foreign currency translation gains 131 94 219 3,929 Other comprehensive income 370 16 852 3,604 Comprehensive income 3,942 4,437 10,898 6,804 Comprehensive income attributable to noncontrolling interests ( 166 ) ( 205 ) ( 348 ) ( 393 ) Comprehensive income attributable to UnitedHealth Group common shareholders $ 3,776 $ 4,232 $ 10,550 $ 6,411 See Notes to the Condensed Consolidated Financial Statements 3 Table of Contents UnitedHealth Group Condensed Consolidated Statements of Changes in Equity (Unaudited) Common Stock Additional Paid-In Capital Retained Earnings Accumulated Other Comprehensive Loss Nonredeemable Noncontrolling Interests Total Equity Three months ended June 30, (in millions) Shares Amount Net Unrealized (Losses) Gains on Investments Foreign Currency Translation (Losses) Gains Balance at March 31, 2025 910 $ 9 $ \u2014 $ 97,934 $ ( 1,832 ) $ ( 1,073 ) $ 5,773 $ 100,811 Net earnings 3,406 149 3,555 Other comprehensive income 239 131 370 Issuances of common stock, and related tax effects 1 \u2014 196 196 Share-based compensation 229 229 Common share repurchases ( 6 ) \u2014 ( 415 ) ( 2,090 ) ( 2,505 ) Cash dividends paid on common shares ($ 2.21 per share) ( 2,000 ) ( 2,000 ) Redeemable noncontrolling interests fair value and other adjustments ( 10 ) ( 10 ) Acquisition and other adjustments of nonredeemable noncontrolling interests ( 19 ) ( 19 ) Distribution to nonredeemable noncontrolling interests ( 158 ) ( 158 ) Balance at June 30, 2025 905 $ 9 $ \u2014 $ 97,250 $ ( 1,593 ) $ ( 942 ) $ 5,745 $ 100,469 Balance at March 31, 2024 920 $ 9 $ \u2014 $ 90,118 $ ( 2,218 ) $ ( 1,221 ) $ 5,682 $ 92,370 Net earnings 4,216 158 4,374 Other comprehensive (loss) income ( 78 ) 94 16 Issuances of common stock, and related tax effects 1 \u2014 196 196 Share-based compensation 210 210 Common share repurchases \u2014 \u2014 3 1 4 Cash dividends paid on common shares ($ 2.10 per share) ( 1,935 ) ( 1,935 ) Redeemable noncontrolling interests fair value and other adjustments ( 36 ) ( 36 ) Acquisition and other adjustments of nonredeemable noncontrolling interests ( 338 ) ( 338 ) Distribution to nonredeemable noncontrolling interests ( 185 ) ( 185 ) Balance at June 30, 2024 921 $ 9 $ 373 $ 92,400 $ ( 2,296 ) $ ( 1,127 ) $ 5,317 $ 94,676 See Notes to the Condensed Consolidated Financial Statements 4 Table of Contents UnitedHealth Group Condensed Consolidated Statements of Changes in Equity (Unaudited) Common Stock Additional Paid-In Capital Retained Earnings Accumulated Other Comprehensive Loss Nonredeemable Noncontrolling Interests Total Equity Six months ended June 30, (in millions) Shares Amount Net Unrealized (Losses) Gains on Investments Foreign Currency Translation (Losses) Gains Balance at January 1, 2025 915 $ 9 $ \u2014 $ 96,036 $ ( 2,226 ) $ ( 1,161 ) $ 5,610 $ 98,268 Net earnings 9,698 297 9,995 Other comprehensive income 633 219 852 Issuances of common stock, and related tax effects 2 \u2014 379 379 Share-based compensation 591 591 Common share repurchases ( 12 ) \u2014 ( 955 ) ( 4,572 ) ( 5,527 ) Cash dividends paid on common shares ($ 4.31 per share) ( 3,912 ) ( 3,912 ) Redeemable noncontrolling interests fair value and other adjustments ( 15 ) ( 15 ) Acquisition and other adjustments of nonredeemable noncontrolling interests 175 175 Distribution to nonredeemable noncontrolling in\ne segment. The following table summarizes the impact of hypothetical changes in market interest rates across the entire yield curve by 1% point or 2% points as of June\u00a030, 2025 on our investment income and interest expense per annum, and the fair value of our investments and debt (in millions, except percentages): June 30, 2025 Increase (Decrease) in Market Interest Rate Investment Income\u00a0Per Annum Interest Expense\u00a0Per Annum Fair\u00a0Value\u00a0of Financial Assets Fair\u00a0Value\u00a0of Financial Liabilities 2 % $ 734 $ 542 $ (4,202) $ (9,288) 1 367 271 (2,150) (5,058) (1) (367) (256) 2,202 6,107 (2) (734) (510) 4,416 13,549 Note: The impact of hypothetical changes in interest rates may not reflect the full 100 or 200 basis point change on interest income and interest expense or on the fair value of financial assets and liabilities as the rates are assumed to not fall below zero. The following table summarizes the impact of hypothetical changes in market interest rates across the entire yield curve by 1% point or 2% points as of June\u00a030, 2025 on our investment income and interest expense per annum, and the fair value of our investments and debt (in millions, except percentages): June 30, 2025 Increase (Decrease) in Market Interest Rate Investment Income\u00a0Per Annum Interest Expense\u00a0Per Annum Fair\u00a0Value\u00a0of Financial Assets Fair\u00a0Value\u00a0of Financial Liabilities 2 % $ 734 $ 542 $ (4,202) $ (9,288) 1 367 271 (2,150) (5,058) (1) (367) (256) 2,202 6,107 (2) (734) (510) 4,416 13,549 Note: The impact of hypothetical changes in interest rates may not reflect the full 100 or 200 basis point change on interest income and interest expense or on the fair value of financial assets and liabilities as the rates are assumed to not fall below zero. Top negative sentences: We discuss these matters, and certain risks that may affect our business operatio\nok Ratings Outlook Senior unsecured debt A2 Negative A+ Negative A Stable A Negative Commercial paper P-1 n/a A-1 n/a F1 n/a AMB-1+ n/a The availability of financing in the form of debt or equity is influenced by many factors, including our profitability, operating cash flows, debt levels, credit ratings, debt covenants and other contractual restrictions, regulatory requirements and economic and market conditions. Best Ratings Outlook Ratings Outlook Ratings Outlook Ratings Outlook Senior unsecured debt A2 Negative A+ Negative A Stable A Negative Commercial paper P-1 n/a A-1 n/a F1 n/a AMB-1+ n/a The availability of financing in the form of debt or equity is influenced by many factors, including our profitability, operating cash flows, debt levels, credit ratings, debt covenants and other contractual restrictions, regulatory requirements and economic and market conditions. Best Ratings Outlook Ratings Outlook Ratings Outlook Ratings Outlook Senior unsecured debt A2 Negative A+ Negative A Stable A Negative Commercial paper P-1 n/a A-1 n/a F1 n/a AMB-1+ n/a The availability of financing in the form of debt or equity is influenced by many factors, including our profitability, operating cash flows, debt levels, credit ratings, debt covenants and other contractual restrictions, regulatory requirements and economic and market conditions. Forward-looking snippets: Readers are cautioned that the statements, estimates, projections or outlook contained in this Management's Discussion and Analysis of Financial Condition and Results of Operations, including discussions regarding financial prospects, economic conditions, trends and uncertainties contained in this Item\u00a02, may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). We expect overall spending on health care to continue to grow in the future, due to inflation, medical technology and pharmaceutical advancement, regulatory requirements, demographic trends in the population and national interest in health and well-being. We expect broad-based competition to continue as the industry adapts to individual and employer needs. 16 Table of Contents Optum Health\u2019s fully accountable value-based care businesses have been impacted by Medicare funding reductions and have also seen continued medical cost trend pressures, which may impact future pricing in the markets we continue to participate. We continue to take a prudent, market-sustainable posture for both new business and maintenance of existing relationships."
}